AR Asset Management Inc. Has $4 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Key Points

• AR Asset Management Inc. increased its holdings in Pfizer Inc. by 17.0%, bringing its total to 157,965 shares worth approximately $4 million.
• Pfizer reported $0.78 earnings per share (EPS) for the last quarter, exceeding analysts' expectations by $0.20, with revenue reaching $14.65 billion.
• The company announced a quarterly dividend of $0.43, equating to an annualized yield of 6.8%, with a payout ratio of 91.49%.

AR Asset Management Inc. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 17.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 157,965 shares of the biopharmaceutical company's stock after purchasing an additional 23,000 shares during the period. AR Asset Management Inc.'s holdings in Pfizer were worth $4,003,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of PFE. Clarity Asset Management Inc. acquired a new position in Pfizer in the fourth quarter valued at $27,000. Gould Capital LLC raised its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the first quarter valued at about $27,000. North Capital Inc. acquired a new position in shares of Pfizer during the first quarter valued at about $28,000. Finally, Bayforest Capital Ltd acquired a new position in shares of Pfizer during the first quarter valued at about $28,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

NYSE PFE opened at $25.16 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock has a market capitalization of $143.05 billion, a PE ratio of 13.38, a P/E/G ratio of 0.89 and a beta of 0.52. The company's 50 day simple moving average is $24.60 and its two-hundred day simple moving average is $24.45.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same period in the prior year, the company posted $0.60 EPS. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer's dividend payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

PFE has been the subject of several recent research reports. The Goldman Sachs Group boosted their target price on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Redburn Atlantic reduced their price objective on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. HSBC reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Berenberg Bank reduced their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Finally, Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.